Date Posted: Mar 7, 2019
Application Deadline: Open Until Filled
We have an opening for a postdoctoral scholar in lung cancer translational research. The candidate will be joining a collaborative research environment between the Labs of Eric Haura and Gina DeNicola at Moffitt. We are looking for a highly motivated and independent postdoctoral research fellow who is interested in working on a project to relate NRF2/KEAP1 mutations and pathway activation with therapeutic responses in lung cancer patients treated with radiation, chemotherapy, and immunotherapy.
The Ideal Candidate:
Successful candidates will have a publication track record demonstrating a strong background in cancer with an interest in translational research. Prior experience is required with some of the following techniques: nucleic acid isolation from human tumor specimens, DNA sequencing, transcriptome analysis, creation of patient cohorts and databases for translational research, statistical analysis of patient datasets. Candidates with prior research experience in translational cancer research working with human tissues and data will be given preference.
This individual will design, conduct and interpret correlative experiments using human lung cancer tumor samples. This individual will create cohorts of patients and determine how changes in NRF2/KEAP1 mutations and downstream pathway activation relate to therapeutic responses. The candidate will join a productive, energetic team of molecular biologists, bioinformaticians, and clinicians within our group.
Credentials and Qualifications:
M.D. or PhD in Molecular Biology, Immunology, Biochemistry, or relevant field.
Interested applicants should send their current CV with recent publications and contact information for three references to Dr. Eric Haura at Eric.Haura@moffitt.org
Moffitt Cancer Center is a premier cancer research institution in the United States. Built in an attractive location, it is the only NCI-designated cancer center in Florida and one of the top institutions in systems medicine and personalized cancer therapy. Moffitt features a number of high-quality core facilities equipped with state-of-the-art instrumentation and a cluster of expertise particularly in adoptive cell therapies.
H. Lee Moffitt Cancer Center & Research Institute is an equal opportunity, affirmative action employer, and a drug free workplace